Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study.

Y-H Zhou1, Q-C Zheng, Z-S Li

  • 1State Key Laboratory of Theoretical and Computational Chemistry, Institute of Theoretical Chemistry, Jilin University, Changchun 130023, China.

Biochimie
|June 3, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circ_0005276 aggravates the development of epithelial ovarian cancer by targeting ADAM9.

European review for medical and pharmacological sciences·2022
Same author

Circ_0005276 aggravates the development of epithelial ovarian cancer by targeting ADAM9.

European review for medical and pharmacological sciences·2020
Same author

Structure-Guided In Vitro to In Vivo Pharmacokinetic Optimization of Propargyl-Linked Antifolates.

Drug metabolism and disposition: the biological fate of chemicals·2019
Same author

Impact of participation in a surgical site infection surveillance network: results from a large international cohort study.

The Journal of hospital infection·2018
Same author

Effect of miR-212 targeting TCF7L2 on the proliferation and metastasis of cervical cancer.

European review for medical and pharmacological sciences·2017
Same author

Secular trends in incidence and recurrence rates of hip fracture: a nationwide population-based study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2016

Genetic variants of Cytochrome P450 2C9 (CYP2C9) can reduce drug metabolism. The CYP2C9*13 variant, with a Leu90Pro substitution, shows decreased activity, impacting drug safety for individuals carrying this allele.

Area of Science:

  • Pharmacogenomics
  • Enzyme kinetics
  • Structural biology

Background:

  • Cytochrome P450 2C9 (CYP2C9) is crucial for metabolizing many clinical drugs.
  • Genetic variations in CYP2C9 can lead to reduced enzyme activity, potentially causing drug toxicity, especially for drugs with a narrow therapeutic index.
  • The CYP2C9*13 allele, identified in Chinese individuals, results from a Leu90Pro substitution and exhibits reduced activity.

Purpose of the Study:

  • To investigate the structure-activity relationship of the CYP2C9*13 variant.
  • To elucidate the structural basis for the reduced catalytic activity of CYP2C9*13 on diclofenac and lornoxicam.

Main Methods:

  • Molecular dynamics simulations were used to build 3D structural models of wild-type CYP2C9*1 and the CYP2C9*13 variant.

Related Experiment Videos

  • Analysis of structural changes caused by the Leu90Pro substitution.
  • Docking studies to identify key enzyme-substrate interactions.

    • Main Results:

    • The CYP2C9*13 variant exhibits significantly reduced in vitro catalytic activity for diclofenac and lornoxicam metabolism.
    • The Leu90Pro substitution leads to structural alterations, including a trans configuration at Pro90-Asp89 and a conformational change in residues 106-108.
    • These structural changes cause the substrate-binding entrance of CYP2C9*13 to shrink, hindering substrate access and reducing catalytic efficiency.

    Conclusions:

    • The reduced enzymatic activity of CYP2C9*13 is primarily due to structural changes that impede substrate binding.
    • Understanding these structure-activity relationships is vital for predicting drug response and potential toxicity in individuals with specific CYP2C9 genetic variants.